Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia pa...
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Untreated
de novo
(
n
=421) and secondary (
n
=189) acute myeloid leukemia (AML) patients ⩾60 years received intensified chemotherapy, including daunorubicin 60 mg/m
2
and etoposide 100 mg/m
2
during days 1, 2, 3 with cytarabine 100 mg/m
2
during days 1–7, with a second induction if needed and one consolidation c...
Alternative Titles
Full title
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3821040
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3821040
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/leu.2011.9
